Redeye leaves a short comment following OncoZenge’s announcement that UCLA has enrolled the first patient in its patient engagement study for BupiZenge. We view this as an encouraging step in the company’s development strategy, providing valuable patient and clinician insights that could strengthen both the upcoming European CTA submission and future US regulatory interactions.
LÄS MER
